Hair loss deal with Allergan to earn Exicure up to $750 million
Exicure (Nasdaq: XCUR), which bills itself as a pioneer in gene regulatory and immunotherapeutic drugs using spherical nucleic acid (SNA) technology, was 17% up after two hours of trading on Thursday.
The reason for this rise was the announcement that the US company had entered into a collaboration, option and license agreement with Ireland-headquartered company Allergan (NYSE: AGN) to discover and develop treatments for hair loss disorders based on Exicure’s proprietary SNA technology.
"This is an exciting opportunity to advance Exicure’s SNA technology in an important new therapeutic area"
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze